

To
BSE Limited
P.J Towers
Dalal Street
Mumbai – 400001

Date: 13.08.2026

Dear Sir,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Ref: Sangam Health Care Products Ltd (BSE Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Sangam Health Care Products Limited held on Thursday, the 13th day of August, 2026, at 4.00 P.M. at the registered office of the Company, the Company the following were duly considered and approved by the Board:

1. Un Audited Financial results for the quarter ended 30.06.2026 (enclosed).
2. Limited Review Report for the quarter ended 30.06.2026 (enclosed).
3. Re Appointment of Mr. Bhagat Reddy Dundumulla as Managing Director of the Company for a further period of five (5) years with effect from September 05, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company
4. Recommendation for the approval of members regarding the reappointment of Mrs. Padma Ghanakota (DIN: 07078176), who retires by rotation and, being eligible, has offered herself for reappointment.
5. Approval of the AGM Notice and Director's Report for the year ended March 31, 2026 along with Annexures thereto.
6. To convene the 32nd AGM of the members of the Company on Wednesday, 30 September 2026, at 9:00 AM. at the Registered Office: Survey No. 182, Yellampet Village, Medchal Mandal, Medchal District, Telangana — 501401.
7. The Register of Members and Share Transfer Books of the company will remain closed from 24.09.2026 to 30.09.2026 (both days inclusive) pursuant to regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of the Board of Directors commenced at 4.00 P.M.(IST) and concluded at 5.15 P.M. (1ST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours truly,

For Sangam Health Care Products Limited



D. Bhagat Reddy
Managing Director
DIN: (07087331)

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated November 11, 2024]

Re-appointment of Managing Director

Si. No.	Particulars	Details
1.	Reason for change viz., appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Bhagat Reddy Dundumulla as an Managing Director of the Company.
2.	Date appointment	Re-appointment as Managing Director of the Company w.e.f. September 05, 2026
3.	Terms of appointment	Re-appointed as Managing Director of the Company for a further period of five (5) years with effect from September 5, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
4.	Brief profile	Mr. Bhagat Reddy Dundumulla is already acting as Managing Director of the Company. He has 12 Years of Experience in manufacturing IV sets and other Medical Disposables
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Bhagat Reddy Dundumulla is not related to any Director of the Company.
6.	No. of Shares held in the Company	2,00,000
7.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular with ref. no. NSE/CML/2018/24 dated June 20, 2018	Mr. Bhagat Reddy Dundumulla is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

For Sangam Health Care Products Limited




D. Bhagat Reddy
Managing Director
DIN: (07087331)

SANGAM HEALTH CARE PRODUCTS LIMITED

182, Yellampet village, Medchal Mandal, Hyderabad, Telangana-501401

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

	Particulars	Quarter ended				(Rs. In Lakhs)
		30-06-2026	31-03-2026	30-06-2025		Year Ended
		Un-Audited	Audited	Un-Audited		31-03-2026
						Audited
1	Income from Operations					
(a)	Net Sales/Income from Operations	302.56	265.50	281.67		1,123.33
(b)	Other Income-	-	2.10	-		2.10
	Total Income	302.56	267.60	281.67		1,125.43
2	Expenditure					
(a)	Cost of Raw material consumed	148.89	100.96	166.21		591.59
(b)	Purchase of stock-in-trade	-	-	-		-
(c)	Change in inventories of Finished Goods Works-in Progress and Stock in Trade	-	-	-		-
(d)	Employees Benefit Expenses	61.98	107.21	40.89		228.68
(e)	Finance Cost	0.21	0.37	0.02		0.91
(e)	Depreciation and Amortization Expenses	1.44	1.87	1.26		5.64
(f)	Other Expenditure	47.13	104.58	62.80		277.90
	Total Expenses	259.65	314.99	271.17		1,104.72
3	Profit from Operations before Extraordinary Items and Exceptional Items (1-2)	42.91	(47.39)	10.49		20.71
4	Exceptional Items	-	-	-		-
9	Profit / (Loss) from Ordinary					
	Activities before tax (7+8)	42.91	(47.39)	10.49		20.71
	Tax expense:					
10	Current tax	11.16	3.82	2.73		5.38
	Deferred tax	1.13	(23.32)	(2.49)		10.00
11	Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	30.63	(27.89)	10.26		5.33
12	Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07		1486.07
14	Earning Per Share (EPS)					
a)	Basic and diluted Eps before Extraordinary	0.02	0.19	0.01		0.04
b)	Basic and diluted Eps after Extraordinary	0.02	0.19	0.01		0.04

Note :

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on 13-08-2026
- The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

For Sangam Healthcare Products Limited

[Signature]
Balagopal

Managing Director
DIN:01712903

Place: Hyderabad
Date: 13-08-2026



M M REDDY & CO.,
Chartered Accountants

Phone: 040 - 23418836

40272617

Mobile: 9848271555

M M R Lion Corp, 4th Floor, HSR Eden, Road No. 2, Banjara Hills, Hyderabad – 500034.TS. E-mail: mmreddyandco@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors,
Sangam Health Care Products Limited

We have reviewed the accompanying statement of Un-Audited Financial Results of **Sangam Health Care Products Limited** for the quarter ended **30th June 2026** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.


The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No.: 010371S

M. Madhusudhana Reddy
Partner
Membership No. 213077
UDIN:26213077IXUMAS2673



Place: Hyderabad
Date: 13-08-2026

